<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Previous clinical trials suggest that the traditional Japanese medicine yokukansan has beneficial effects on the behavioral and psychological symptoms of <z:hpo ids='HP_0000726'>dementia</z:hpo> (BPSD) </plain></SENT>
<SENT sid="1" pm="."><plain>The present study was conducted to elucidate the efficacy of yokukansan on BPSD in patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Thirteen Japanese patients (9 men and 4 women) who were diagnosed as having vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) according to the diagnostic criteria of NINDS-AIREN were subjected to the open-label clinical trial in which yokukansan (7.5g/day) has been given for 4 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Their mean age was 71.2±6.5 years </plain></SENT>
<SENT sid="4" pm="."><plain>The BPSD was evaluated using the Neuropsychiatric Inventory (NPI), cognitive function was evaluated by the Mini-Mental State Examination (MMSE), the activities of daily living was evaluated by Barthel index (BI) and Disability Assessment for <z:hpo ids='HP_0000726'>Dementia</z:hpo> (DAD), and the <z:hpo ids='HP_0002071'>extrapyramidal signs</z:hpo> were evaluated by United <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's Disease</z:e> Rating Scale (UPDRS) </plain></SENT>
<SENT sid="5" pm="."><plain>The mean NPI was 33.0±17.3 and 23.6±13.9 for the baseline and after treatment, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>It was significantly improved after treatment (p&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>In the NPI-subcategories, there was a significant improvement in <z:hpo ids='HP_0000713'>agitation</z:hpo> and <z:hpo ids='HP_0000734'>disinhibition</z:hpo> after the treatment </plain></SENT>
<SENT sid="8" pm="."><plain>There was no significant change in MMSE, BI, DAD or UPDRS before and after the treatment </plain></SENT>
<SENT sid="9" pm="."><plain>There was no adverse effect during the treatment period </plain></SENT>
<SENT sid="10" pm="."><plain>The present results suggest that yokukansan is beneficial for the treatment of BPSD in VaD patients </plain></SENT>
</text></document>